SCHEMBL2736785

SCHEMBL2736785

CCCCn1cc(-c2cc3ccccc3o2)cc(C(=O)NCc2ccccc2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.53
KMT2A Q03164 2/20 0.52
CNR2 P34972 8/20 0.52
CNR1 P21554 6/20 0.52
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
POLB P06746 1/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
BRD4 O60885 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736787 0.93 MAOB (0.45) MAOBKMT2ACNR2CNR1SMN1; SMN2
SCHEMBL2736786 0.91 L3MBTL1 (0.54) MAOBKMT2ACNR2CNR1ALDH1A1
SCHEMBL250298 0.84 CNR2 (0.61) CNR2CNR1TP53POLBBRD4
SCHEMBL2736811 0.84 CNR2 (0.54) KMT2ACNR2CNR1ALDH1A1HPGD
SCHEMBL2736789 0.82 KDM4E (0.62) MAOBKMT2ACNR2CNR1ALDH1A1
SCHEMBL2736850 0.81 CNR2 (0.60) CNR2CNR1ALDH1A1HPGDSMN1; SMN2
SCHEMBL2736805 0.81 CNR2 (0.58) CNR2CNR1TP53POLBBRD4
SCHEMBL2736810 0.80 CNR2 (0.56) KMT2ACNR2CNR1L3MBTL1POLB
SCHEMBL2736842 0.80 CNR2 (0.61) KMT2ACNR2CNR1ALDH1A1HPGD
SCHEMBL2736790 0.80 CNR2 (0.52) CNR2CNR1ALDH1A1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R MAOB 928/4885KMT2A 2963/4885CNR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.